We are proud to announce the publication of our latest clinical results in Annals of surgical oncology, detailing
the first-in-human study of CEB-01, a novel biodegradable membrane for the local delivery of SN-38 after
tumour resection. This multicenter trial was designed to establish the recommended phase 2 dose (RP2D)
while evaluating safety, efficacy, and pharmacokinetics.

Key Highlights:
✅ Positive Safety Profile: Demonstrated preliminary efficacy at the RP2D.
✅ Targeted Delivery: Sustained and controlled release of SN-38 for up to 28 days.
✅ Reduced Systemic Exposure: Achieved localized treatment with lower systemic impact compared to
intravenous alternatives.

The use of CEB-01 after resection of retroperitoneal sarcomas represents an innovative shift in how we address
local recurrences. This is an important step in our mission to develop localized, effective solutions for cancer
patients.

https://pubmed.ncbi.nlm.nih.gov/41998462/